A5014849163- Endometrial and Cervical Cancer Treatments
- Ovarian cancer diagnosis and treatment
- Uterine Myomas and Treatments
- Estrogen and related hormone effects
- Endometriosis Research and Treatment
- Cancer Genomics and Diagnostics
- Sarcoma Diagnosis and Treatment
- Gestational Trophoblastic Disease Studies
- Prostate Cancer Treatment and Research
- Congenital Diaphragmatic Hernia Studies
- HER2/EGFR in Cancer Research
- PI3K/AKT/mTOR signaling in cancer
- Histone Deacetylase Inhibitors Research
- Management of metastatic bone disease
- Cancer Treatment and Pharmacology
- Maternal and fetal healthcare
- Lymphoma Diagnosis and Treatment
- Advanced Breast Cancer Therapies
- Genetic factors in colorectal cancer
- Prenatal Screening and Diagnostics
- TGF-β signaling in diseases
- Cervical Cancer and HPV Research
- Cancer Mechanisms and Therapy
- Lung Cancer Research Studies
- Cancer survivorship and care
NRG Oncology
2012-2023
Roswell Park Comprehensive Cancer Center
2010-2022
University of Iowa
2021
Carver Bible College
2021
University at Buffalo, State University of New York
2021
Gynecologic Oncology Group
2007-2019
The University of Texas Southwestern Medical Center
2011-2016
University of Oklahoma Health Sciences Center
2005-2016
Corewell Health Blodgett Hospital
2016
Spectrum Health
2016
Purpose To compare whole-abdominal irradiation (WAI) and doxorubicin-cisplatin (AP) chemotherapy in women with stage III or IV endometrial carcinoma having a maximum of 2 cm postoperative residual disease. Patients Methods Four hundred twenty-two patients were entered onto this trial. Of 396 assessable patients, 202 randomly allocated to receive WAI, 194 AP. Irradiation dosage was 30 Gy 20 fractions, 15-Gy boost. Chemotherapy consisted doxorubicin 60 mg/m cisplatin 50 every 3 weeks for seven...
Stage III or IVA endometrial cancer carries a significant risk of systemic and locoregional recurrence.
The primary objective was to determine if vaginal cuff brachytherapy and chemotherapy (VCB/C) increases recurrence-free survival (RFS) compared with pelvic radiation therapy (RT) in high-intermediate high-risk early-stage endometrial carcinoma.
Limitations of the paclitaxel-doxorubicin-cisplatin (TAP) regimen in treatment endometrial cancer include tolerability and cumbersome scheduling. The Gynecologic Oncology Group studied carboplatin plus paclitaxel (TC) as a noninferior alternative to TAP.GOG0209 was phase III, randomized, noninferiority, open-label trial. Inclusion criteria were stage IV, recurrent cancers; performance status 0-2; adequate renal, hepatic, marrow function. Prior radiotherapy and/or hormonal therapy permitted,...
This phase III randomized trial (NCT00954174) tested the null hypothesis that paclitaxel and carboplatin (PC) is inferior to ifosfamide (PI) for treating uterine carcinosarcoma (UCS).Adults with chemotherapy-naïve UCS or ovarian (OCS) were randomly assigned PC PI 3-week cycles 6-10 cycles. With 264 events in patients UCS, power an overall survival (OS) hybrid noninferiority design was 80% a hazard ratio (HR) of 1.2 against 13% greater death rate on type I error 5% one-tailed test.The study...
To determine if paclitaxel added to ifosfamide as first-line treatment for advanced uterine carcinosarcoma (CS) improves overall survival (OS), progression-free (PFS), response, and toxicity.Eligible patients had measurable stage III or IV, persistent, recurrent CS. Random assignment was between 2.0 g/m2 intravenously (IV) daily 3 days (arm 1) 1.6 IV plus 135 mg/m2 by 3-hour infusion day 1 2). Mesna administered similarly (both arms); filgrastim began on 4 Cycles were repeated every 21 up...
Purpose There is no consensus on the best regimen for primary treatment of low-risk gestational trophoblastic neoplasia (GTN). Patients and Methods Two commonly used single-drug regimens were compared with respect to proportion patients meeting criteria a complete response (CR) in randomized phase III trial conducted by Gynecologic Oncology Group. Eligibility was purposefully broad maximize generalizability results included WHO risk score 0 6 metastatic disease (limited lung lesions < 2...
Platinum and taxane compounds have demonstrated activity in uterine carcinosarcoma (malignant mixed Mullerian tumor). Ifosfamide plus paclitaxel is the regimen with established superiority based on a randomized phase III trial conducted through Gynecologic Oncology Group. However, toxicity, multiday schedule, limited of this support further development novel regimens. Our primary objective was to estimate antitumor toxicity carboplatin patients carcinosarcomas.Eligible had advanced stage...
The status of p53 in a tumor can be inferred by next-generation sequencing (NGS) or immunohistochemistry (IHC). We examined the association between IHC and sequence whether alone, integrated with TP53 NGS, predicts outcome.From GOG-86P, randomized phase II study chemotherapy combined either bevacizumab temsirolimus advanced endometrial cancer, 213 cases had protein expression data measured NGS data. An analysis was designed to integrate presence absence mutation. These variables were further...
5505 Background: Patients with stage III/IVA uterine cancer (UC) carry high risk of systemic and local recurrence. Chemotherapy was shown to reduce recurrence, however the failure remains high. Methods: The primary endpoint this open label, randomized phase III trial determine if treatment cisplatin volume-directed radiation followed by carboplatin paclitaxel for 4 cycles (C-RT, experimental arm) reduces rate recurrence or death (i.e., increases recurrence-free survival, RFS) when compared 6...
To evaluate the efficacy and safety of second uterine curettage in lieu chemotherapy for patients with low-risk, nonmetastatic gestational trophoblastic neoplasia (GTN) to whether response is independent patient age, World Health Organization (WHO) risk score, registration human chorionic gonadotropin (hCG) level, lesion size, depth myometrial invasion measured on ultrasound examination.This was a cooperative group multicenter prospective phase II study. Prestudy testing included...